Organisation paid for research Program year 2025 Source: CMS Open Payments

Brainstorm Research

Neither a doctor nor a teaching hospital

Research payments

$2,012,374

90 payments

Through program year 2025, Brainstorm Research is reported as receiving $2,012,374 in research payments, across 90 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $255,649 19
2024 Research $550,436 23
2023 Research $513,441 31
2022 Research $692,849 17

Breakdown

Who paid Research payments · program years 2022–2025
  1. Eli Lilly and Company $986,962 15 payments
  2. Sage Therapeutics, Inc. $550,979 6 payments
  3. AbbVie, Inc. $207,786 20 payments
  4. Pfizer Inc. $119,381 12 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $73,793 15 payments
  6. Jazz Pharmaceuticals Inc. $32,928 9 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $24,628 2 payments
  8. H. Lundbeck A S $9,413 8 payments
  9. SK Life Science, Inc. $6,505 3 payments
Studies the money was for Research payments · program years 2022–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $625,876 4 payments
  2. Study to Evaluate SAGE-324 in Participants With Essential Tremors $338,769 3 payments
  3. A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor $212,209 3 payments
  4. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $176,902 2 payments
  5. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $168,608 18 payments
  6. A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $148,124 1 payment
  7. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $115,602 10 payments
  8. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $49,131 9 payments
  9. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $36,539 1 payment
  10. A Long-Term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution $32,928 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record